LuerJack in Norway - ConceptoMed AS and Vingmed AS signed a marketing, sales and distribution agreement for the hospital market
ConceptoMed AS is delighted to announce a new partner for the Norwegian hospital market. We have entered into a distribution agreement with Vingmed AS granting exclusive rights for marketing, sales and distribution of the LuerJack syringes in the hospital market in Norway.
US FDA 510(k) Clearance for Luer-Jack® Slip syringe
ConceptoMed AS received FDA 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first size of the Luer-Jack® syringe.
US Patent issued for Luer-Jack®
On the 10th of May 2016, the United States Patent and Trademark office issued an official document granting the US patent for Luer-Jack. The US Luer-Jack patent is an important part of the families of similar filed applications in all important markets world wide, and is a fundamental member of the Luer-Jack patent family.
Oversubscribed private placement - total €10,5 Million (100 MNOK) in ConceptoMed AS
The Board of Directors of ConceptoMed AS announce the final completion of the successful private placement of equity in ConceptoMed AS for the period January-February 2016. The placement round was oversubscribed.
Oversubscribed Private Placement of €1.42 Million
The Board of Directors of ConceptoMed AS have the pleasure of announcing the successful completion of a private placement of equity in ConceptoMed AS. The share issue was oversubscribed and provided the company with 12 new shareholders. Gross proceeds from the private placement amounted to NOK 11,550,000 (€1.42 Million)